Liang Haoran, Chen Zihao, Mo Chunwei, Han Yanjiang, Liu Qingxing, Tang Ganghua
GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):1189-1199. doi: 10.1007/s00259-024-06978-2. Epub 2024 Nov 13.
Somatostatin receptor (SSTR) antagonists have recently emerged as preferable radiotracers for SSTR-targeted imaging and therapy. This study aimed to design a novel SSTR antagonist, [F]AlF-NOTA-Asp-PEG-JR11, and compare its preclinical performance with the previously reported antagonist, [F]AlF-NOTA-JR11, and the agonist [Ga]Ga-DOTA-TATE.
[F]AlF-NOTA-Asp-PEG-JR11 was synthesized via a one-step radiolabeling process involving [F]AlF chelation. The binding affinity, internalization, and cellular uptake were evaluated using AR42J/SSTR + cells. Biodistribution and PET/CT imaging were conducted in mice bearing xenografted AR42J/SSTR + or HCT116/SSTR- tumor xenografts.
[F]AlF-NOTA-Asp-PEG-JR11 was manually synthesized within 30 min with an uncorrected radiochemical yield of 39.56 ± 3.25% (n > 5) and radiochemical purity (RCP) exceeding 99% (n > 5). [F]AlF-NOTA-Asp-PEG-JR11 demonstrated excellent in vivo stability over 2 h (RCP > 95%). Among AR42J cells, [F]AlF-NOTA-Asp-PEG-JR11 exhibited high affinity, specific uptake, and low internalization, similar to [F]AlF-NOTA-JR11. Biodistribution and micro-PET/CT imaging studies revealed comparable tumor uptake between [F]AlF-NOTA-Asp-PEG-JR11 and [F]AlF-NOTA-JR11 (9.26 ± 0.49 vs. 10.18 ± 0.82%ID/g, p = 0.147) at 60 min post-injection (p.i), both were significantly higher than [Ga]Ga-DOTA-TATE (6.79 ± 0.29%ID/g, p = 0.001). Co-injecting the corresponding inhibitor significantly reduced the tumor uptake of all three tracers. Notably, [F]AlF-NOTA-Asp-PEG-JR11 reached peak tumor uptake at 30 min p.i. and exhibited the lowest uptake and fastest clearance in most normal organs, including the kidney, bone, liver, and muscle, resulting in the highest and increasing tumor-to-background ratios (TBR) over time among the three tracers.
The synthesis of [F]AlF-NOTA-Asp-PEG-JR11 is efficient, with high radiochemical yield and RCP. [F]AlF-NOTA-Asp-PEG-JR11 exhibits excellent in vivo stability, high tumor uptake, and superior TBR, making it a promising potential tracer for imaging SSTR-positive tumors.
生长抑素受体(SSTR)拮抗剂最近已成为用于SSTR靶向成像和治疗的优选放射性示踪剂。本研究旨在设计一种新型SSTR拮抗剂[F]AlF-NOTA-Asp-PEG-JR11,并将其临床前性能与先前报道的拮抗剂[F]AlF-NOTA-JR11以及激动剂[Ga]Ga-DOTA-TATE进行比较。
[F]AlF-NOTA-Asp-PEG-JR11通过涉及[F]AlF螯合的一步放射性标记过程合成。使用AR42J/SSTR+细胞评估其结合亲和力、内化和细胞摄取。在携带异种移植的AR42J/SSTR+或HCT116/SSTR-肿瘤异种移植物的小鼠中进行生物分布和PET/CT成像。
[F]AlF-NOTA-Asp-PEG-JR11在30分钟内手动合成,未校正的放射化学产率为39.56±3.25%(n>5),放射化学纯度(RCP)超过99%(n>5)。[F]AlF-NOTA-Asp-PEG-JR11在2小时内表现出优异的体内稳定性(RCP>95%)。在AR42J细胞中,[F]AlF-NOTA-Asp-PEG-JR11表现出高亲和力、特异性摄取和低内化,与[F]AlF-NOTA-JR11相似。生物分布和微型PET/CT成像研究显示,注射后60分钟时,[F]AlF-NOTA-Asp-PEG-JR11和[F]AlF-NOTA-JR11之间的肿瘤摄取相当(分别为9.26±0.49与10.18±0.82%ID/g,p=0.147),两者均显著高于[Ga]Ga-DOTA-TATE(6.79±0.29%ID/g,p=0.001)。共同注射相应的抑制剂显著降低了所有三种示踪剂的肿瘤摄取。值得注意的是,[F]AlF-NOTA-Asp-PEG-JR11在注射后30分钟达到肿瘤摄取峰值,并且在包括肾脏、骨骼、肝脏和肌肉在内的大多数正常器官中摄取最低且清除最快,导致在三种示踪剂中随着时间推移肿瘤与背景比值(TBR)最高且不断增加。
[F]AlF-NOTA-Asp-PEG-JR11的合成效率高,具有高放射化学产率和RCP。[F]AlF-NOTA-Asp-PEG-JR11表现出优异的体内稳定性、高肿瘤摄取和优越的TBR,使其成为用于成像SSTR阳性肿瘤的有前景的潜在示踪剂。